Journal of Medical Virology

Global Convalescent Plasma Therapy Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022
Health, General Health, Infection, Journal of Medical Virology, Someren-Eind, GSK, Disease, IND, Immunoglobulin G, Immunoglobulin M, Laboratory, Virology, Severe acute respiratory syndrome coronavirus 2, Immunity, Antibody, Patient, Hospital, CPT, RNA, Mortality, Coronavirus, Collection, MERS, US, Application, Houston Methodist Hospital, Safety, Branches of microbiology, Immunoglobulin A, Journal, CDSCO, Plasma, Mucous membrane, FDA, COVID-19, Pharmaceutical industry

The "Convalescent Plasma Therapy Global Market Report 2022, By Application, By End-Users, By Antibody type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Convalescent Plasma Therapy Global Market Report 2022, By Application, By End-Users, By Antibody type" report has been added to ResearchAndMarkets.com's offering.
  • In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate.
  • The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market.
  • The convalescent plasma therapy market consists of sales of convalescent plasma obtained from patients who have recovered from an infection.

Global Dengue Testing Industry Landscape 2021-2026; Dominated by Abbott Labs, NovaTec Immundiagnostica, Euroimmun, Roche, Thermo Fisher Scientific, and InBios Int'l - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 23, 2021
Health, Infectious Diseases, Laboratory, Disease, Fever Dream, Journal of Medical Virology, USD, Thermo Fisher Scientific, Pan American Health Organization, PerkinElmer, Death, Journal, Malaria, Abbott Laboratories, Dengue virus, Government, COVID-19, Branches of microbiology, Philippine Red Cross, Incidence, Population, Climate, Fever, Awareness, Dengue fever, Prevalence, Virology, CAGR, Vaccine, Growth, PRC

Dengue viruses and the virus that causes COVID-19 virus cause similar symptoms in the early stages.

Key Points: 
  • Dengue viruses and the virus that causes COVID-19 virus cause similar symptoms in the early stages.
  • So, most of the people are confusing it to be dengue at getting themselves tested for dengue too.
  • The overall incidence of dengue, as well as the explosive outbreaks of dengue, has been increasing dramatically over the last several years.
  • The major companies that are functioning in the global dengue testing market include Abbott Laboratories, NovaTec Immundiagnostica GmbH, Euroimmun AG (PerkinElmer), F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and InBios International, Inc.

Nanosonics Announces Juama as New Distributor in Mexico

Retrieved on: 
Tuesday, December 7, 2021
Biotechnology, Medical Devices, Infectious Diseases, Health, Radiology, HPV16, Risk, Fungus, STI, Molecular imaging, Growth, Journal of Medical Virology, EPR, Trophon, Bacteria, Google Images, Radiopharmaceutical, Patient, Â, Decontamination, Virus, Multimedia, ASX, HLD, NAN, Shaw, Solution, Compliance, Hydrogen peroxide, Hospital, Radiology, Medical imaging, Video game console, Medical device, Nanosonics, Juama S.A. de V.C, NANOSONICS, JUAMA S.A. DE V.C

as its new distributor for the trophon2 device, accessories, consumables and service in Mexico.

Key Points: 
  • as its new distributor for the trophon2 device, accessories, consumables and service in Mexico.
  • View the full release here: https://www.businesswire.com/news/home/20211207005061/en/
    The trophon2 device from Nanosonics, a leader in infection prevention.
  • We are pleased to have Juama represent our company and our innovative trophon HLD device in Mexico, said Ken Shaw, president of North America for Nanosonics.
  • Juama is very knowledgeable about the diagnostic imaging and infection prevention industry and will be an integral part of Nanosonics growth in this region, continued Shaw.